WOODCLIFF LAKE, N.J., June 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon nasal spray is a generic version of Novartis’ Miacalcin(R). Annual U.S. sales of Miacalcin were approximately $112 million in 2008, according to IMS Health data.
Important information about calcitonin-salmon nasal spray
Calcitonin-salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years post menopause with low bone mass relative to healthy premenopausal females.
Calcitonin-salmon nasal spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated.
Because Calcitonin is a polypeptide, the possibility of a systemic allergic reaction exists.
Please read full prescribing information available at www.parpharm.com/products.
About Par
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.
Safe Harbor Statement
Certain statements in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company’s filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.
CONTACT: Allison Wey, Senior Director, Investor Relations and Corporate
Affairs of Par Pharmaceutical Companies, Inc., +1-201-802-4000
Web site: http://www.parpharm.com/
